Palo Alto, CA (PRWEB) February 20, 2014
Glooko Inc., makers of an advanced diabetes management technology platform, announced today it is launching a new product, Glooko Population Tracker, at February’s HIMSS conference. The latest platform from Glooko is intended to aid health systems and payer groups to more effectively care for their patients with diabetes by offering the ability to easily identify at-risk, patient-specific blood glucose trends. The HIMSS conference will occur between February 24th, 2014 and February 26th, 2014 in Orlando, Florida; Glooko will be presenting the new platform at Booth #503 as part of Samsung Electronic’s Connected Health module.
Glooko Population Tracker features flags that deliver clear visibility to a care manager if a patient is experiencing potentially harmful amounts of hyperglycemic (high blood glucose) or hypoglycemic (low blood glucose) events. Because patients upload their data from all major meters using Glooko on their current personal mobile phone or tablet, Glooko Population Tracker can enable timely care for at-risk patients in-between clinic visits. Tracking at-risk patients is critical for health system and payer groups that are looking to reduce hospitalizations or shifting their focus to Accountable Care models where effective therapy and cost savings take precedence.
According to ‘The United States of Diabetes’ report published by UnitedHealthCare, the average yearly costs of a person with diabetes with complications are nearly five times as high as the average yearly costs of a patient without diabetes. A study by Stanford University researchers determined that hypoglycemia costs nearly $13 Billion per year in direct hospitalizations in the US alone. “Our mission is to create positive outcomes and lower costs to the health system through the right combination of patient engagement, provider engagement and population management analytics,” said Rick Altinger, Glooko CEO. “Glooko Population Tracker tackles the costs of diabetes complications by putting the power of meaningful interventions in the hands of clinicians and care managers before complications show up in their patient population.”
The launch of Glooko Population Tracker follows a series of major announcements from the company since the start of 2014. In late January the company announced its partnership with Joslin Diabetes Center, the world’s preeminent institution in diabetes research and clinical care. The stated purpose of the partnership is to jointly deploy a diabetes management system capable of predictive care to health systems, governments, and payer groups. At the start of the year, Glooko announced it had raised a $7 million from a series of notable investors including Samsung Ventures Investment Group.
Glooko’s FDA 510(k) cleared diabetes management system, consisting of the Glooko MeterSync, the engaging patient mobile application (app) for both iOS and Android, and an assortment of web tools, allows glucose data to be downloaded from dozens of meters that are used by tens of millions of people. To download the data, a user simply connects their glucose meter to their mobile device using the Glooko Application and Glooko MeterSync. This data is then available to providers and care management teams through Glooko’s provider dashboard and can be integrated into EHR’s and other systems. Glooko currently supports data transfer from 29 glucose meters worldwide.
About Glooko Inc.
Glooko is an innovative Silicon Valley company with a unique diabetes management solution for patients, health systems, and payer groups. Glooko’s products – the Glooko mobile apps, MeterSync Cable for iOS and Android, and the Glooko Web Dashboard – enable clinicians to remotely access their patients’ blood glucose readings and other related data. The company’s system allows people with diabetes to download their glucose readings to their mobile device. Glooko was founded in 2010 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin, and Dr. Russell Hirsch.